摘要
目的:探讨多巴胺联合布地奈德治疗对肺炎患儿临床效果及血清CRP、sICAM-1、TNF-α水平的影响。方法:选取2018年9月-2019年9月256例肺炎患儿,随机分为两组,对照组加用布地奈德治疗,研究组加用多巴胺联合布地奈德治疗。比较两组WBC(白细胞计数)、TNF-α(肿瘤坏死因子-α)、sICAM-1(可溶性细胞间黏附因子-1)、CRP(C反应蛋白)、IL-8(白细胞介素-8)、IL-6(白细胞介素-6)血清细胞因子水平,比较两组住院时间及肺部啰音、气喘、咳嗽、退热消失时间,以及临床疗效、不良反应。结果:两组治疗后各项血清细胞因子水平均低于治疗前(P<0.05),研究组治疗后WBC、TNF-α、sICAM-1、CRP、IL-8、IL-6水平均低于对照组(P<0.05);研究组住院时间及肺部啰音、气喘、咳嗽、退热消失时间均短/早于对照组(P<0.05);研究组总有效率高于对照组(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:肺炎患儿采用多巴胺联合布地奈德治疗,不良反应未增加,血清细胞因子水平有显著改善,临床症状得到有效缓解,临床疗效确切,建议临床推广应用。
Objective:To investigate the effect of Dopamine combined with Budesonide and on serum CRP,sICAM-1 and TNF-α levels in children with pneumonia.Method:A total of 256 children with pneumonia from September 2018 to September 2019 were selected and randomly divided into two groups.The control group was treated with Budesonide,and the study group was treated with Dopamine combined with Budesonide.The serum levels of WBC,TNF-α,sICAM-1,CRP,IL-8 and IL-6 were compared between the two groups.The clinical efficacy and adverse reactions were compared between the two groups.Result:After treatment,the levels of serum cytokines in the two groups were lower than those before treatment (P<0.05).After treatment,the levels of WBC,TNF-α,sICAM-1,CRP,IL-8 and IL-6 in the study group were lower than those in the control group (P<0.05);the hospitalization time and disappearance time of pulmonary rales,asthma,cough and fever in the study group were shorter/earlier than those in the control group (P<0.05);the effective rate of the study group was higher than that of the control group (P<0.05).There was no significant difference in the incidence of adverse reactions (P>0.05).Conclusion:The use of Dopamine combined with Budesonide in the treatment of children with pneumonia,adverse reactions do not increase,serum cytokine levels significantly improve,clinical symptoms effectively relieve,the clinical curative effect is accurate,it is recommended clinical application.
作者
杨琛
YANG Chen(Jingshan People’s Hospital,Jingshan 431800,China)
出处
《中外医学研究》
2021年第9期28-31,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
